New chemo formula may reduce Alcohol-Like reactions in breast cancer patients

NCT ID NCT06537752

Recruiting now Knowledge-focused Sponsor: Boryung Pharmaceutical Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study observes over 1,000 breast cancer patients receiving a special version of the chemotherapy drug docetaxel that contains no ethanol (alcohol). The goal is to see how often patients experience alcohol-like symptoms such as flushing or dizziness during or shortly after treatment. Researchers hope this information will help make chemotherapy safer and more tolerable.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: non-ethanol formulation docetaxel
What this could lead to: If successful, this study could help doctors better manage side effects during breast cancer chemotherapy, potentially improving patient comfort.
What could go wrong: This is an observational study, not a treatment trial. It won't test whether the drug works against cancer, only how often ethanol-related symptoms occur. Results may not change current practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Chung-Ang University Hospital
RECRUITING

Seoul, 06973, South Korea
Uijeongbu Eulji Medical Center, Eulji University
NOT_YET_RECRUITING

Uijeongbu-si, 11759, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.